The PASTIS trial

The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The PASTIS trial : Testing tadalafil for possible use in vascular cognitive impairment. / Pauls, Mathilde M. H.; Binnie, Lauren R.; Benjamin, Philip; Betteridge, Shai; Clarke, Brian; Dhillon, Mohani-Preet K.; Ghatala, Rita; Hainsworth, Fearghal A. H.; Howe, Franklyn A.; Khan, Usman; Kruuse, Christina; Madigan, Jeremy B.; Moynihan, Barry; Patel, Bhavini; Pereira, Anthony C.; Rostrup, Egill; Shtaya, Anan B. Y.; Spilling, Catherine A.; Trippier, Sarah; Williams, Rebecca; Young, Robin; Barrick, Thomas R.; Isaacs, Jeremy D.; Hainsworth, Atticus H.

In: Alzheimer's & Dementia, Vol. 18, No. 12, 2022, p. 2393-2402.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Pauls, MMH, Binnie, LR, Benjamin, P, Betteridge, S, Clarke, B, Dhillon, M-PK, Ghatala, R, Hainsworth, FAH, Howe, FA, Khan, U, Kruuse, C, Madigan, JB, Moynihan, B, Patel, B, Pereira, AC, Rostrup, E, Shtaya, ABY, Spilling, CA, Trippier, S, Williams, R, Young, R, Barrick, TR, Isaacs, JD & Hainsworth, AH 2022, 'The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment', Alzheimer's & Dementia, vol. 18, no. 12, pp. 2393-2402. https://doi.org/10.1002/alz.12559

APA

Pauls, M. M. H., Binnie, L. R., Benjamin, P., Betteridge, S., Clarke, B., Dhillon, M-P. K., Ghatala, R., Hainsworth, F. A. H., Howe, F. A., Khan, U., Kruuse, C., Madigan, J. B., Moynihan, B., Patel, B., Pereira, A. C., Rostrup, E., Shtaya, A. B. Y., Spilling, C. A., Trippier, S., ... Hainsworth, A. H. (2022). The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment. Alzheimer's & Dementia, 18(12), 2393-2402. https://doi.org/10.1002/alz.12559

Vancouver

Pauls MMH, Binnie LR, Benjamin P, Betteridge S, Clarke B, Dhillon M-PK et al. The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment. Alzheimer's & Dementia. 2022;18(12):2393-2402. https://doi.org/10.1002/alz.12559

Author

Pauls, Mathilde M. H. ; Binnie, Lauren R. ; Benjamin, Philip ; Betteridge, Shai ; Clarke, Brian ; Dhillon, Mohani-Preet K. ; Ghatala, Rita ; Hainsworth, Fearghal A. H. ; Howe, Franklyn A. ; Khan, Usman ; Kruuse, Christina ; Madigan, Jeremy B. ; Moynihan, Barry ; Patel, Bhavini ; Pereira, Anthony C. ; Rostrup, Egill ; Shtaya, Anan B. Y. ; Spilling, Catherine A. ; Trippier, Sarah ; Williams, Rebecca ; Young, Robin ; Barrick, Thomas R. ; Isaacs, Jeremy D. ; Hainsworth, Atticus H. / The PASTIS trial : Testing tadalafil for possible use in vascular cognitive impairment. In: Alzheimer's & Dementia. 2022 ; Vol. 18, No. 12. pp. 2393-2402.

Bibtex

@article{71dcb1bce2b544eca3701aabdb9a7cf8,

title = "The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment",

abstract = "Introduction: There are few randomized clinical trials in vascular cognitive impairment (VCI). This trial tested the hypothesis that the PDE5 inhibitor tadalafil, a widely used vasodilator, increases cerebral blood flow (CBF) in older people with symptomatic small vessel disease, the main cause of VCI. Methods: In a double-blind, placebo-controlled, cross-over trial, participants received tadalafil (20 mg) and placebo on two visits ≥7 days apart (randomized to order of treatment). The primary endpoint, change in subcortical CBF, was measured by arterial spin labelling. Results: Tadalafil increased CBF non-significantly in all subcortical areas (N = 55, age: 66.8 (8.6) years) with greatest treatment effect within white matter hyperintensities (+9.8%, P =.0960). There were incidental treatment effects on systolic and diastolic blood pressure (–7.8, –4.9 mmHg; P <.001). No serious adverse events were observed. Discussion: This trial did not identify a significant treatment effect of single-administration tadalafil on subcortical CBF. To detect treatment effects may require different dosing regimens.",

keywords = "cerebral blood flow, clinical trials, PDE5, small vessel disease, tadalafil, vascular cognitive impairment, vascular cognitive impairment and dementia",

author = "Pauls, {Mathilde M. H.} and Binnie, {Lauren R.} and Philip Benjamin and Shai Betteridge and Brian Clarke and Dhillon, {Mohani-Preet K.} and Rita Ghatala and Hainsworth, {Fearghal A. H.} and Howe, {Franklyn A.} and Usman Khan and Christina Kruuse and Madigan, {Jeremy B.} and Barry Moynihan and Bhavini Patel and Pereira, {Anthony C.} and Egill Rostrup and Shtaya, {Anan B. Y.} and Spilling, {Catherine A.} and Sarah Trippier and Rebecca Williams and Robin Young and Barrick, {Thomas R.} and Isaacs, {Jeremy D.} and Hainsworth, {Atticus H.}",

note = "Publisher Copyright: Alzheimer's & Dementia{\textcopyright} 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2022",

doi = "10.1002/alz.12559",

language = "English",

volume = "18",

pages = "2393--2402",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "12",

}

RIS

TY - JOUR

T1 - The PASTIS trial

T2 - Testing tadalafil for possible use in vascular cognitive impairment

AU - Pauls, Mathilde M. H.

AU - Binnie, Lauren R.

AU - Benjamin, Philip

AU - Betteridge, Shai

AU - Clarke, Brian

AU - Dhillon, Mohani-Preet K.

AU - Ghatala, Rita

AU - Hainsworth, Fearghal A. H.

AU - Howe, Franklyn A.

AU - Khan, Usman

AU - Kruuse, Christina

AU - Madigan, Jeremy B.

AU - Moynihan, Barry

AU - Patel, Bhavini

AU - Pereira, Anthony C.

AU - Rostrup, Egill

AU - Shtaya, Anan B. Y.

AU - Spilling, Catherine A.

AU - Trippier, Sarah

AU - Williams, Rebecca

AU - Young, Robin

AU - Barrick, Thomas R.

AU - Isaacs, Jeremy D.

AU - Hainsworth, Atticus H.

PY - 2022

Y1 - 2022

N2 - Introduction: There are few randomized clinical trials in vascular cognitive impairment (VCI). This trial tested the hypothesis that the PDE5 inhibitor tadalafil, a widely used vasodilator, increases cerebral blood flow (CBF) in older people with symptomatic small vessel disease, the main cause of VCI. Methods: In a double-blind, placebo-controlled, cross-over trial, participants received tadalafil (20 mg) and placebo on two visits ≥7 days apart (randomized to order of treatment). The primary endpoint, change in subcortical CBF, was measured by arterial spin labelling. Results: Tadalafil increased CBF non-significantly in all subcortical areas (N = 55, age: 66.8 (8.6) years) with greatest treatment effect within white matter hyperintensities (+9.8%, P =.0960). There were incidental treatment effects on systolic and diastolic blood pressure (–7.8, –4.9 mmHg; P <.001). No serious adverse events were observed. Discussion: This trial did not identify a significant treatment effect of single-administration tadalafil on subcortical CBF. To detect treatment effects may require different dosing regimens.

AB - Introduction: There are few randomized clinical trials in vascular cognitive impairment (VCI). This trial tested the hypothesis that the PDE5 inhibitor tadalafil, a widely used vasodilator, increases cerebral blood flow (CBF) in older people with symptomatic small vessel disease, the main cause of VCI. Methods: In a double-blind, placebo-controlled, cross-over trial, participants received tadalafil (20 mg) and placebo on two visits ≥7 days apart (randomized to order of treatment). The primary endpoint, change in subcortical CBF, was measured by arterial spin labelling. Results: Tadalafil increased CBF non-significantly in all subcortical areas (N = 55, age: 66.8 (8.6) years) with greatest treatment effect within white matter hyperintensities (+9.8%, P =.0960). There were incidental treatment effects on systolic and diastolic blood pressure (–7.8, –4.9 mmHg; P <.001). No serious adverse events were observed. Discussion: This trial did not identify a significant treatment effect of single-administration tadalafil on subcortical CBF. To detect treatment effects may require different dosing regimens.

KW - cerebral blood flow

KW - clinical trials

KW - PDE5

KW - small vessel disease

KW - tadalafil

KW - vascular cognitive impairment

KW - vascular cognitive impairment and dementia

U2 - 10.1002/alz.12559

DO - 10.1002/alz.12559

M3 - Journal article

C2 - 35135037

AN - SCOPUS:85124543065

VL - 18

SP - 2393

EP - 2402

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

SN - 1552-5260

IS - 12

ER -

ID: 313702946